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ABSTRACT
Background: Macronutrient intake varies substantially between in-
dividuals, and there is evidence that this variation is partly ac-
counted for by genetic variants.
Objective: The objective of the study was to identify common
genetic variants that are associated with macronutrient intake.
Design: We performed 2-stage genome-wide association (GWA)
meta-analysis of macronutrient intake in populations of European
descent. Macronutrients were assessed by using food-frequency
questionnaires and analyzed as percentages of total energy con-
sumption from total fat, protein, and carbohydrate. From the dis-
covery GWA (n = 38,360), 35 independent loci associated with
macronutrient intake at P , 5 3 1026 were identified and taken
forward to replication in 3 additional cohorts (n = 33,533) from the
DietGen Consortium. For one locus, fat mass obesity-associated
protein (FTO), cohorts with Illumina MetaboChip genotype data
(n = 7724) provided additional replication data.
Results: A variant in the chromosome 19 locus (rs838145) was
associated with higher carbohydrate (b 6 SE: 0.25 6 0.04%; P =
1.68 3 1028) and lower fat (b 6 SE: 20.21 6 0.04%; P = 1.57 3
1029) consumption. A candidate gene in this region, fibroblast
growth factor 21 (FGF21), encodes a fibroblast growth factor in-
volved in glucose and lipid metabolism. The variants in this locus
were associated with circulating FGF21 protein concentrations (P,
0.05) but not mRNA concentrations in blood or brain. The body
mass index (BMI)–increasing allele of the FTO variant (rs1421085)
was associated with higher protein intake (b 6 SE: 0.10 6 0.02%;
P = 9.96 3 10210), independent of BMI (after adjustment for BMI,
b 6 SE: 0.08 6 0.02%; P = 3.15 3 1027).
Conclusion: Our results indicate that variants in genes involved in
nutrient metabolism and obesity are associated with macronutrient
consumption in humans. Trials related to this study were registered
at clinicaltrials.gov as NCT00005131 (Atherosclerosis Risk in
Communities), NCT00005133 (Cardiovascular Health Study),
NCT00005136 (Family Heart Study), NCT00005121 (Framingham
Heart Study), NCT00083369 (Genetic and Environmental Determi-
nants of Triglycerides), NCT01331512 (InCHIANTI Study), and
NCT00005487 (Multi-Ethnic Study of Atherosclerosis). Am J
Clin Nutr 2013;97:1395–402.
INTRODUCTION
Considerable variation in dietary choices exists across in-
dividuals. Human eating behavior is driven by many psycho-
logical and social factors, including culture, economics, and
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health beliefs. There is evidence from twin and family studies
that consumption of major macronutrients has a genetic com-
ponent, with estimated heritability ranging from 8% to 70% (1).
Importantly, the specific genes that might underlie these asso-
ciations have yet to be elucidated. The identification of genetic
loci underlying macronutrient intake could provide insight into
the biology of human dietary behaviors. Genome-wide linkage
studies have identified several chromosomal regions for mac-
ronutrient intake (2–5). Some notable candidate genes within the
linkage region include pro-opiomelanocortin (POMC), adiponectin
(ADIPOQ), melanocortin receptor 4 (MC4R), and peroxisome
proliferator-activated receptor g (PPARg). Furthermore, candi-
date gene association studies have focused primarily on genes
involved in the central control of food intake, such as dopamine
receptor (DRD2) (6, 7) and serotonin receptor (HTR2A) (8, 9),
and the obesity genes fat mass obesity-associated protein (FTO)
(10–13) and MC4R (11, 13, 14). Many of the results are in-
consistent or lack replication to confirm the initial findings. The
disparate findings between the studies may be a result of the
differences in the study population, dietary assessment methods,
or statistical methods used.
To identify common genetic variants associated with macro-
nutrient intake, we conducted a meta-analysis of genome-wide
association (GWA)5 analyses of carbohydrate, protein, and total
fat intake by using data from 12 discovery cohorts (n = 38,360)
from the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) Consortium Nutrition Working Group
(15). The top signals from this analysis were combined in a joint
analysis with data from a second macronutrient meta-analysis of
data from 3 cohorts (n = 33,533) from the DietGen Consortium
(16). For single nucleotide polymorphisms (SNPs) that were di-
rectly genotyped on the Illumina MetaboChip, data from an ad-
ditional 3 cohorts (n = 7724) were used as replication data.
SUBJECTS AND METHODS
GWA cohorts
GWAwas conducted in 37,537 subjects from the following 12
cohorts from the CHARGE Consortium Nutrition Working Group:
the Atherosclerosis Risk in Communities Study; the Cardiovascular
Health Study; the European Prospective Investigation into Cancer
and Nutrition–Norfolk (EPIC-Norfolk); the Family Heart Study;
the Fenland Study; the Framingham Heart Study; the Genetics of
Lipid Lowering Drugs and Diet Network (GOLDN) Study; the
Health, Aging, and Body Composition (Health ABC) Study; the
InCHIANTI Study; the Multi-Ethnic Study of Atherosclerosis
(MESA); the Rotterdam Study; and the Young Finns Study. Each
cohort’s study protocol was reviewed and approved by their re-
spective institutional review board (see Supplemental Table S1
under “Supplemental data” in the online issue).
Stage 2 replication MetaboChip cohorts
Data from the Gene-Lifestyle interactions And Complex traits
Involved in Elevated disease Risk (GLACIER) Study from
Sweden, the Malmö Diet and Cancer Study from Sweden, and
The Hellenic study of Interactions between Snps and Eating in
Atherosclerosis Susceptibility (n = 7724) were used to replicate
SNPs identified by stage 1 GWA that was genotyped by the
MetaboChip.
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Stage 2 replication GWA cohorts
A second GWA meta-analysis of macronutrient intake was
conducted in parallel by the DietGen Consortium [n = 33,533
(16)]. The consortium is composed of 3 US population–based
cohorts: the Health Professionals Follow-Up Study (17), the
Nurses’ Health Study (18), and the Women’s Genome Health
Study (19). The DietGen Consortium performed GWA analysis
by using the same methods as the CHARGE Consortium.
Assessment of macronutrient intake
Average dietary intake was assessed by using food-frequency
questionnaires (FFQs). The type of FFQ used in each study varied
slightly, with this variation generally designed to best capture the
dietary habits of the population under study (see Supplemental
Table S2 under “Supplemental data” in the online issue). Among
these various CHARGE cohorts, 87% of the FFQs had been
validated against other dietary assessment methods. On the basis
of the responses to each FFQ and study-specific nutrient data-
bases, usual nutrient consumption was calculated. The present
analysis focused on the percentage of energy from total fat,
protein, and carbohydrate intake.
Heritability estimates
In the Framingham Heart Study and the Family Heart Study,
the heritability of macronutrient adjusted for age and sex was
estimated by using the variance components method in Se-
quential Oligogenic Linkage Analysis Routines (SOLAR; Texas
Biomedical Research Institute).
Genotyping and GWA analysis
Genome-wide genotyping was conducted by using Affymetrix
or Illumina platforms. Each study performed quality control for
genotyped SNPs on the basis of minor allele frequency, call rate,
and departure from Hardy-Weinberg equilibrium (see Supple-
mental Table S3 under “Supplemental data” in the online issue).
Phased haplotypes from HapMap CEU (build 35 or 36) were
used to imputew2.5 million autosomal SNPs by using a Hidden
Markov model algorithm implemented in MACH (20), IMPUTE
(21), or BimBam (22). Study-specific GWA analyses were con-
ducted for each macronutrient by using genotyped and imputed
SNP dosages assuming an additive genetic model. The base
model included age and sex for all studies and study-specific
covariates (eg, study site) and population stratification principal
components when applicable (model 1). In a second model
(model 2), BMI was added to the covariates in model 1. SNPs
with low minor allele frequency (,1%), low imputation quality
(MACH: Rsq , 0.3; or IMPUTE: proper info , 0.4) were re-
moved. The results from each study were combined in a fixed-
effects meta-analysis with inverse variance weights by using
METAL software (23). To account for population stratification,
the association results from individual studies as well as meta-
analyses were adjusted for genomic control.
To increase the power to detect significant associations, a joint
analysis with results from the DietGen Consortium (n = 33,533)
was conducted for 35 independent genomic regions containing
SNPs with P , 1026, a threshold that was selected on the basis
of the deviation of observed P values from the expected (see
Supplemental Figure S1 under “Supplemental data” in the online
issue). The tag SNPs for each genomic region were selected by
using HapMap CEU (release rel#23a NCBI B36) linkage dis-
equilibrium structure with a cutoff of r2 . 0.5 within a 250-kb
window. Of the top 35 independent loci, the top SNP in the FTO
locus was evaluated in a second replication group (n = 7724) with
MetaboChip data. The results from the 2 genome-wide meta-
analyses and MetaboChip data were combined by using a fixed-
effects inverse variance–weighted meta-analysis. For the joint
analysis, genome-wide significance was considered at the Bon-
ferroni-corrected threshold of P , 5 3 1028.
Expression quantitative trait loci analysis
Proxy SNPs (D# . 0.8 or r2 . 0.8) of the top SNPs
(rs838145) on 19q13.33 were queried in expression SNP data-
bases that included results from the following tissues: fresh
lymphocytes (24, 25), fresh leukocytes (26), peripheral blood
monocytes, fresh leukocytes (26), omental and subcutaneous
adipose tissue (27, 28), whole-blood samples (27, 29), and liver
(28, 30, 31).
Assessment of fibroblast growth factor 21 protein
concentrations
In participants in the Baltimore Longitudinal Study on Aging,
serum fibroblast growth factor 21 (FGF21) was measured with
ELISA (Quantikine Human FGF-21 ELISA; R&D Systems) by
using samples that were stored continuously at 2708C until the
time of analysis of FGF21. The samples were analyzed at Johns
Hopkins Hospital in the laboratory of one of the investigators
(RDS). The intra- and interassay CVs were 2.8% and 7.0%,
respectively. The assay has a minimum limit of detection of 4.6
pg/mL. No samples were below the lower limit of detection.
RESULTS
The mean macronutrient intake assessed through FFQs in the
12 discovery GWA studies were similar across studies and were,
on average, 17 6 1.3%, 33 6 2.5%, and 48 6 2.9% for protein,
fat, and carbohydrate, respectively (see Supplemental Table S4
under “Supplemental data” in the online issue). Heritability
estimates for protein, carbohydrate, and fat intake were similar
in the 2 cohorts evaluated: 17 6 0.02%, 20 6 0.03%, and 20 6
0.03%, respectively, in the Family Heart Study; 17 6 0.02%, 20
6 0.02%, and 23 6 0.03%, respectively, in the Framingham
Heart Study.
The meta-analysis of stage 1 discovery genome scans of
macronutrient intake showed modest deviation from the expected
distribution of P values under the null hypothesis, particularly
for protein intake (see Supplemental Figure S1 under “Supple-
mental data” in the online issue). The genomic control values for
the meta-analysis of carbohydrate, fat, and protein intake were
1.04, 1.04, and 1.06, respectively, for the model adjusted for age
and sex (base model) and 1.04, 1.05, and 1.05, respectively, for the
BMI-adjusted model. Genome-wide significant associations were
observed with a locus in an w7-kb region on 4q28, near the
mastermind-like 3 (MAML3) gene for protein intake (Table 1; see
Supplemental Table S5 under “Supplemental data” in the online
issue). The strongest association was observed for rs1350036
where the minor allele was associated with lower protein intake
(bCHARGE 6 SE: 20.14 6 0.02%; P = 1.72 3 10
28). The signal
remained significant after adjustment for BMI (bCHARGE 6 SE:
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20.15 6 0.02%; P = 6.60 3 1029). No genome-wide significant
associations were observed for carbohydrate and fat intake.
From stage 1 analysis, we took forward the SNPs that repre-
sented the 35 most significant loci (P , 1026) in either the base
model (Table 1) or the BMI-adjusted model (see Supplemental
Table S5 under “Supplemental data” in the online issue). These
SNPs were analyzed jointly with data from the DietGen Consor-
tium and 3 studies with MetaboChip data for the FTO (rs1421085)
locus because this SNP was directly genotyped on the chip. In
joint meta-analyses, genome-wide significant associations were
observed for rs1421085 in the FTO locus on chromosome 16 in
the model 1 for protein intake (Table 1), where the BMI-increasing
minor allele was associated with higher protein intake (bJoint 6
SE: 0.10 6 0.02%; P = 9.96 3 10210). In the BMI-adjusted
model, a small reduction in the strength of association was ob-
served (bJoint 6 SE: 0.08 6 0.02%; P = 3.15 3 10
27).
Genome-wide significant associations were also observed on
19q13.33 for both fat and carbohydrate intake in the joint analysis
(Table 1). The minor allele of rs838145 was associated with
a higher percentage of energy intake from carbohydrate for the
base model (bJoint 6 SE: 0.23 6 0.04%; P = 3.13 3 10
27) and
for the BMI-adjusted model (bJoint 6 SE: 0.256 0.04%; P = 1.7
3 1028) and a lower percentage of energy intake from fat for the
base model (bJoint 6 SE:20.226 0.04%; P = 4.483 10
210) and
for the BMI-adjusted model (bJoint 6 SE: 20.21 6 0.04%; P =
1.57 3 1029).
We identified FGF21 as a candidate gene in the 19q13.33
region, which encodes a hormone that regulates glucose and
lipid metabolism (Figure 1, A and B). To investigate whether
FGF21 could be the gene underlying this signal, we explored the
association of rs838145 with the expression of the FGF21 gene
and protein. First, we used an existing expression quantitative
trait loci database of cis-gene expression with the use of data
from genome-wide expression analysis in relevant tissues that
express FGF21 including liver, adipose, and blood (see Sup-
plemental Table S6 under “Supplemental data” in the online
issue). Data show the expression of multiple genes in association
with SNPs in high linkage disequilibrium with rs838145; how-
ever, the expression of FGF21 was not supported by the data.
Second, to assess the association of rs838145 with circulating
concentrations of FGF21 protein, we used plasma FGF21 con-
centrations in 377 individuals in the Baltimore Longitudinal
Study on Aging. The minor allele of rs838145, which was as-
sociated with a higher percentage of energy from carbohydrate
and a lower percentage of energy from fat, was significantly
associated with higher FGF21 protein concentrations (b 6 SE:
36 6 17 pg/mL; P = 0.01), after adjustment for age and sex.
This association remained significant after further adjusting the
analyses for BMI (b 6 SE: 32 6 17 pg/mL; P = 0.02).
The SNP (rs1350036) in the 4q28 region that reached genome-
wide significance in stage 1 for protein intake was not replicated
in stage 2 and was not significant in the joint analysis for the base
model (bJoint 6 SE: 20.07 6 0.02%; P = 3.49 3 10
25; Table 1)
or in the BMI-adjusted model (bJoint 6 SE:20.076 0.02%; P =
2.19 3 1025).
DISCUSSION
In this study, we identified genome-wide significant associations
of a locus on 19q13.33 for carbohydrate and fat intake, with re-
ciprocal directions of association, and with the FTO locus for
protein intake. FTO was one of the first BMI loci to be identified
through GWA scans and has been consistently associated with
obesity in various cohorts (32, 33). The association of variants in
FTO with protein intake in our study was largely unchanged after
adjustment for BMI, suggesting that this association is not me-
diated by BMI. The FTO SNP reported in this analysis
(rs1421085) is in high linkage disequilibrium (r2 . 0.97) with
SNPs showing the strongest association with BMI (rs993609,
rs9930506) (32–34). Previous studies have investigated the as-
sociation of FTO variants with food intake (35–37), hypothesiz-
ing an effect through the regulation of hunger and satiety (38).
The focus of these studies was primarily on total energy intake
rather than on specific macronutrients. Overall, the evidence was
weak, but our findings highlight the importance of further in-
vestigation to clarify the interrelations of the FTO gene, macro-
nutrient and energy intake, and body weight.
It is notable that, with the exception of FTO, other loci identified
in previous linkage analyses (2–5) and candidate gene association
studies (6–9, 11, 13, 14) of macronutrient intake were not among
the top signals in our study. There have been 4 linkage studies of
macronutrient intake, and although each study identified signifi-
cant linkage regions, there were none that were consistent across
the studies (2–5). It is possible that there are macronutrient loci
that are specific to the families in each study. However, discrep-
ancies may also be a result of differences in study population,
methods for dietary assessment, or statistical methods used.
We report novel associations of a locus on 19q13.33 with
higher carbohydrate and lower fat consumption, independent of
BMI. One gene in this region with potential links to macronu-
trient intake was FGF21, which encodes a hormone produced
primarily in the liver that is an important regulator of glucose
and lipid metabolism (39, 40). In vitro, FGF21 promotes insulin-
independent glucose uptake through the transcription of GLUT1
in rodent and human adipocytes (41). Pharmacologic doses of
FGF21 improve glucose clearance and insulin sensitivity and
lower plasma triglycerides and free fatty acids in diabetic and
obese animal models (41–44). FGF21 also plays a critical role in
regulating metabolic adaptation in nutritional states in which the
primary source of energy is derived from fatty acids. During
prolonged starvation or consumption of a ketogenic diet (high
fat, low carbohydrate), FGF21 increases lipolysis in adipose
tissue and increases ketogenesis and b-oxidation in the liver (45,
46). In humans, the role of FGF21 is not well defined. Some
reports have linked FGF21 with BMI and other metabolic var-
iables, but results are not consistent (47–49). In our study, we
observed a significant association between the 19q13.33 variant
with circulating protein concentrations of FGF21 but not with
gene expression levels in liver, fat, and blood tissues. If FGF21
is the gene underlying the signal on 19q13.33, it is possible that
there is a metabolic shift in glucose and fat metabolism, such
that carriers of the minor allele preferentially consume more
energy from carbohydrate and less from fat.
This study, along with the DietGen Consortium meta-analysis
(16), is the largest GWA study of macronutrient intake in Eu-
ropean ancestry cohorts. Interestingly, both studies identified
associations with the locus on 19q13.33 but for different mac-
ronutrients. The DietGen Consortium observed a genome-wide
significant association of 19q13.33with protein intake, whereas we
found associations with fat and carbohydrate intake. Although the
GENOME-WIDE ASSOCIATION OF MACRONUTRIENT INTAKE 1399
FIGURE 1. Regional association plot of 19q13.33 and the FTO locus region. The panels show –log10 P values for SNPs that passed quality control from the
stage 1 meta-analysis of intakes of carbohydrate (A), fat (B), and protein (C) as percentages of total energy adjusted for age, sex, and study-specific covariates
(eg, study site, population-stratification principal components when applicable). The SNPs shown are those within 1 Mb of the index SNP: rs8183145 on
chromosome 19 (A, B) and rs1421085 on chromosome 16 (C). The degree of linkage disequilibrium (r2) is shown from low (,0.2; light gray) to high ($0.8;
black). chr, chromosome; cM, centimorgan; Mb, mega base pair; SNP, single nucleotide polymorphism.
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reasons for these differences are unclear, it is possible that this
locus is not specific to intake of any single macronutrient. Total
dietary energy is derived from different macronutrients; therefore,
when there is a change in the percentage of energy from one
macronutrient, a change in one or both of the other macronutrients
may occur in the opposite direction. Thus, the results of the 2
studies suggest that this locus is associated with dietary macro-
nutrient composition rather than with the consumption of a specific
macronutrient.
Although the associations reported in this study are significant,
the effects are small in magnitude. These estimates may be
underestimated because of measurement errors of macronutrient
intake from FFQs. The FFQ is a commonly used dietary as-
sessment tool in epidemiologic studies because it is feasible to
use in large studies and accurately rank-orders individuals across
the spectra of foods and nutrients; however, the validity of es-
timates varies across nutrients and populations. Of the cohorts
involved in the CHARGE discovery meta-analysis, 10 of 12 used
validated FFQs. Nevertheless, the clinical significance of dif-
ferences in macronutrient intake ofw0.2%, even when extended
over a lifetime, is not clear. In this light, the size and scope of
our study are important strengths to detect such a modest impact
of genetics, and our findings are most relevant to elucidate the
potential underlying biology of very complex human dietary
behaviors. Given the complexity of the investigated trait, it is
likely that other as yet unidentified loci, as well as other genetic
differences such as copy number variants, contribute to macro-
nutrient intake. Furthermore, replication of these findings in
non-European cohorts will be needed to determine whether the
identified loci are associated with macronutrient intake in other
populations.
In conclusion, we report associations of a locus on chromo-
some 19 with carbohydrate and fat intake and of the FTO locus
with protein intake. We also propose FGF21 as one strong
candidate for the former association, and our findings support
the need for further functional assessment and fine mapping of
19q13.33. Our results support a role of common genetic variants
on macronutrient consumption in humans.
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